Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Bone Therapeutics partners Erasme University Hospital to start Phase IIa trial in osteoporosis with bone cell therapy

Bone Therapeutics : 17 April, 2013  (Company News)
Bone Therapeutics' partner, the Rheumatology Department of Erasme University Hospital (Brussels, Belgium), initiates a Phase IIa trial with its lead bone cell therapy product PREOB for the treatment of severe osteoporosis patients who do not respond to pharmacological treatment.


PREOB is Bone Therapeutics first-in-class autologous osteoblastic (bone forming) cell therapy product.  Due to its unique mechanism of action, PREOB could have a significant role to play in the treatment of severe osteoporosis, where the majority of current treatments do not provide bone forming/anabolic activity as their mechanism of action and where over 40 percent of patients under treatment are still losing bone mass and fracture PREOB is currently in two pivotal Phase III trials for the treatment of osteonecrosis and non-union fractures.



The Phase IIa study is a six month open-label trial enrolling 20 patients with severe osteoporosis who do not respond to anti-osteoporotic treatment.  PREOB will be administered via a single intravenous infusion, and the primary endpoints of the trial will be cell body distribution and bone markers. The trial is the first of its kind to be initiated globally and will be run at the Erasme University Hospital (Free University of Brussels (ULB), Belgium).



Bone Therapeutics has been granted from the Free University of Brussels an exclusive worldwide license for PREOB currently in Phase III clinical trials. Bone Therapeutics was founded in 2006 based on the pioneering works carried out at Erasme University Hospital-ULB, Brussels, Belgium. The company still maintains close collaborations with scientific experts from various universities such as Prof Gangji who is now head of the Rheumatology Department of the ULB Erasme Hospital.



Osteoporosis is a disease causing bone fragility and weakness and affects over 200 million people worldwide. Due to aging populations and growing awareness of the disease, the global market for osteoporosis therapeutics is expected to reach $8.8 billion in 2015.



Enrico Bastianelli, Chief Executive Officer of Bone Therapeutics, commented: "We are delighted to be expanding the potential of our lead product PREOB to osteoporosis, a large disease area with significant unmet need, under the existing agreement that we have with the Free University of Brussels."



Valerie Gangji, Head of Rheumatology, Erasme University Hospital commented: "We are very excited to be investigating the potential of PREOB in treatment-resistant osteoporosis, where PREOB's unique mechanism of action could have a real impact on patients.  A new treatment such as PREOB that could reduce the risk of fracture and form new bone could significantly improve the quality of life of these osteoporotic patients."


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo